WHO PHARMACEUTICALS NEWSLETTER Prepared in Collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden

Total Page:16

File Type:pdf, Size:1020Kb

WHO PHARMACEUTICALS NEWSLETTER Prepared in Collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden WHO PHARMACEUTICALS NEWSLETTER prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden The aim of this Newsletter is to disseminate information on the No. 6, 2004 safety and efficacy of pharmaceutical products, based on information received from our network of “drug information officers” and other sources such as specialized bulletins and journals, as well as partners in News & Issues WHO. The information is produced in the form of résumés in English, This is the final issue of the newsletter for the year 2004. We full texts of which may be obtained hope that the information covered has been useful in your work on request from: and in keeping abreast of recent developments in drug safety. As stated in the previous issues, we have now established a Quality Assurance and Safety: system for electronic mailing of the newsletter to accommodate Medicines, EDM–HTP those of you who cannot be included in our postal mailing list. World Health Organization, To join this list, please send an email to [email protected] 1211 Geneva 27, Switzerland with the message text: subscribe WHO-PHN. E-mail address: [email protected] Fax: +41 22 791 4730 This has been a busy year with many new priority areas emerging in drug safety. The World Alliance of Patient Safety Further information on adverse was launched in October and the WHO drug safety programme reactions may be obtained from the will work closely with the Alliance, particularly in reporting WHO Collaborating Centre for medication errors and conducting research on the impact of International Drug Monitoring, safety measures in promoting patient safety solutions. The Stora Torget 3, issue of safety of medicines in children, with emphasis on off- S-753 20 Uppsala, Sweden label use, is also recognized as an important and neglected area Tel: 46-18-65.60.60 that needs to be brought to the attention of WHO. Fax: 46-18-65.60.80 E-mail: [email protected] The Twenty-seventh Annual Meeting of National Centres Internet:http://www.who-umc.org participating in the WHO Programme for International Drug prepared in collaboration with the Monitoring was held from 4 to 6 October, in Dublin, Ireland. We WHO Collaborating Centre for include, in this issue, the observations on the questions International Drug Monitoring, discussed by the working groups at the meeting. We hope these Uppsala, Sweden observations will stimulate innovative and collaborative _________________________ approaches to pharmacovigilance. Last, but not least, we wish Contents all our readers good health and happiness in 2005. Regulatory matters Safety of medicines Feature TABLE OF CONTENTS REGULATORY MATTERS ACTRA-RX AND YILISHEN -- Presence of undeclared sildenafil ................................................................. 1 ADALIMUMAB -- Serious infections if used together with anakinra ............................................................ 1 ANTIDEPRESSANTS -- Label to warn of increased suicidality in children; Patient Medication Guide to advise on risks and precautions to be taken ................................................. 1 ATORVASTATIN -- Interaction with grapefruit juice ................................................................................ 2 BLACK COHOSH COMBINATION #2; YELLOW DOCK COMBINATION #3 -- Presence of aristolochic acid........ 2 CELECOXIB -- Withdrawn in Turkey...................................................................................................... 2 EPOETIN ALFA -- Label change to reflect thrombosis risk ........................................................................ 2 ETANERCEPT, INFLIXIMAB -- Reports of serious infections ..................................................................... 2 INFLIXIMAB -- Lymphoma warning added to label.................................................................................. 2 ISOTRETINOIN -- Enhancement to risk management programme ............................................................ 3 LEVOTHYROXINE SODIUM -- Dysphagia and risk of choking .................................................................... 3 MIFEPRISTONE -- Important labelling changes proposed......................................................................... 3 PERGOLIDE MESYLATE -- Label change: risk of cardiac valvulopathy ........................................................ 4 REMINYL AND AMARYL -- Reports of medication errors ........................................................................... 4 VALDECOXIB -- Label updated to warn about skin reactions .................................................................... 4 SAFETY OF MEDICINES CHOLINESTERASE INHIBITORS -- Reports of cardiac arrhythmias ............................................................ 5 CYCLO-OXYGENASE-2 INHIBITORS -- Plans to review all medicines in this class ........................................ 5 ETHINYLESTRADIOL / CYPROTERONE -- Increased risk of thrombosis....................................................... 5 HERBAL MEDICINES -- Cardiovascular ADRs reported to Health Canada.................................................... 5 INFLUENZA VIRUS VACCINE -- Interactions with drugs........................................................................... 6 MEDROXYPROGESTERONE -- Effect on bone mineral density ................................................................... 6 PAMIDRONATE DISODIUM, ZOLEDRONIC ACID -- Spontaneous reports of osteonecrosis of the jaw ............. 6 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) -- ADRAC reviews use in children and adolescents . 7 TERBINAFINE -- Reports of blood dyscrasias ......................................................................................... 7 TRICYCLIC ANTIDEPRESSANTS -- Overdose risk .................................................................................... 7 FEATURE Twenty-seventh Annual Meeting of Representatives of the National Centres participating in the WHO Programme for International Drug Monitoring: Observations from Working Groups .................. 8 REGULATORY MATTERS ACTRA-RX AND use of anakinra and other TNF antidepressant drugs, including blocking agents, and since the selective serotonin reuptake YILISHEN adalimumab is also a TNF inhibitors (SSRIs), in children Presence of undeclared blocking agent, Abbott and adolescents with major Laboratories warn that the depressive disorder (MDD), sildenafil combination of anakinra with obsessive compulsive disorder USA. The Food and Drug adalimumab is not (OCD) or other psychiatric Administration (FDA) has recommended. In addition, disorders. The analysis showed warned consumers not to Abbott is also warning that rare a greater risk of suicidality purchase or to consume Actra- but serious anaphylactic and during the first few months of Rx or Yilishen, two products hypersensitivity reactions as treatment in those receiving promoted and offered for sale well as haematologic reactions antidepressants. The average on websites as dietary including aplastic anaemia have risk of such events on drug was supplements for treating been reported in patients 4%, twice the placebo risk of erectile dysfunction and treated with adalimumab; 2 %. According to the FDA enhancing sexual performance treatment should be Public Health Advisory, the in men. The FDA has found that discontinued immediately when expanded warning statements these products contain such hypersensitivity reactions will highlight the following: undeclared prescription are observed and patients strength sildenafil. Sildenafil, should be advised to seek • Antidepressants increase the when taken together with medical attention if signs and risk of suicidal thinking and certain prescription drugs symptoms of haematologic behaviour (suicidality) in containing nitrates (such as events (e.g. persistent fever, children and adolescents nitroglycerin) may cause a pallor, bruising, bleeding) are with MDD and other significant lowering of blood noticed. psychiatric disorders. pressure to an unsafe level. Reference: • Anyone considering the use These drugs should therefore 'Dear Health-care Professional' of an antidepressant in a be taken only under medical letter from Abbott Laboratories, child or adolescent for any supervision. The FDA is 5 November 2004. Available on the clinical use must balance the advising consumers who use Internet at www.fda.gov risk of increased suicidality Actra-Rx or Yilishen to stop with the clinical need. taking these products and to ANTI- consult their health-care • Patients on therapy should providers regarding erectile DEPRESSANTS be observed closely for dysfunction treatment. clinical worsening, Label to warn of suicidality, or unusual Reference: increased suicidality in changes in behaviour. FDA Talk Paper, 2 November 2004. children; Patient Available on the Internet at • Families and caregivers www.fda.gov Medication Guide to should be advised to closely advise on risks and observe the patient and to ADALIMUMAB precautions to be communicate with the taken prescriber. Serious infections if used together with USA. The FDA has directed • A statement regarding whether the particular drug anakinra manufacturers of all antidepressant drugs to include is approved for any USA. Abbott Laboratories, in a boxed warning and expanded paediatric indication(s) and, consultation with FDA, has warning statements in the if so, which one(s). updated the prescribing labels of these products that The FDA has advised that a information for adalimumab alert health-care providers to Patient Medication
Recommended publications
  • Attachment: Extract from Clinical Evaluation Bosentan
    AusPAR Attachment 1 Extract from the Clinical Evaluation Report for Bosentan Proprietary Product Name: Tracleer Sponsor: Actelion Pharmaceuticals Australia Pty Ltd First round report: 25 October 2016 Second round report: 3 February 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About the Extract from the Clinical Evaluation Report · This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities. · The words [Information redacted], where they appear in this document, indicate that confidential information has been deleted. · For the most recent Product Information (PI), please refer to the TGA website <https://www.tga.gov.au/product-information-pi>.
    [Show full text]
  • LOKELMA Is Sodium Zirconium Cyclosilicate, a Potassium Binder
    HIGHLIGHTS OF PRESCRIBING INFORMATION • For oral suspension: 10 g per packet (3) These highlights do not include all the information needed to use LOKELMA™ safely and effectively. See full prescribing information for ------------------------------ CONTRAINDICATIONS ----------------------------­ LOKELMA™. None. (4) ----------------------- WARNINGS AND PRECAUTIONS ---------------------­ LOKELMA™ (sodium zirconium cyclosilicate) for oral suspension • Gastrointestinal Adverse Events in Patients with Motility Disorders. Initial U.S. Approval: [2018] (5.1) --------------------------- INDICATIONS AND USAGE -------------------------­ • Edema. (5.2) LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults. (1) ------------------------------ ADVERSE REACTIONS ----------------------------­ Most common adverse reactions with LOKELMA: mild to moderate edema. Limitation of Use (6.1) LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ---------------------- DOSAGE AND ADMINISTRATION ---------------------­ • Recommended starting dose is 10 g administered three times a day for ------------------------------ DRUG INTERACTIONS ----------------------------­ up to 48 hours. (2.1) In general, other oral medications should be administered at least 2 hours • For maintenance treatment, recommended dose is 10 g once daily. (2.1) before
    [Show full text]
  • Hormones in Pregnancy
    SYMPOSIUM Hormones in pregnancy Pratap Kumar, Navneet Magon1 Department of Obstetrics and Gynecology, Kasturba Medical College, Manipal University, Manipal, Karnataka, 1Air Force Hospital, Nathu Singh Road, Kanpur Cantt, Uttar Pradesh, India ABSTRACT The endocrinology of human pregnancy involves endocrine and metabolic changes that result from physiological alterations at the boundary between mother and fetus. Progesterone and oestrogen have a great role along with other hormones. The controversies of use of progestogen and others are discussed in this chapter. Progesterone has been shown to stimulate the secretion of Th2 and reduces the secretion of Th1 cytokines which maintains pregnancy. Supportive care in early pregnancy is associated with a significant beneficial effect on pregnancy outcome. Address for correspondence: Prophylactic hormonal supplementation can be recommended for all assisted reproduction Dr. Navneet Magon, techniques cycles. Preterm labor can be prevented by the use of progestogen. The route of Head, Department of Obstetrics administration plays an important role in the drug’s safety and efficacy profile in different and Gynecology, Air Force trimesters of pregnancy. Thyroid disorders have a great impact on pregnancy outcome and Hospital, Nathu Singh Road, needs to be monitored and treated accordingly. Method of locating review: Pubmed, scopus Kanpur Cantt, U.P. India. E‑ mail: [email protected] Key words: Oestrogen, hormones, progesterone, thyroid INTRODUCTION about 250 mg/day. Almost all of the progesterone produced by the placenta enters the placenta, contrast to oestrogen. Steroid hormones like progesterone have been extensively Progesterone production is independent of he precursor studied in the literature with controversies in early available, fetal status including the wellbeing.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • Predictive Model of Bosentan-Induced Liver Toxicity in Japanese Patients with Pulmonary Arterial Hypertension
    Canadian Journal of Physiology and Pharmacology Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension Journal: Canadian Journal of Physiology and Pharmacology Manuscript ID cjpp-2019-0656.R1 Manuscript Type: Article Date Submitted by the 24-Mar-2020 Author: Complete List of Authors: Yorifuji, Kennosuke; Shinko Hospital Uemura, Yuko; Shinko Hospital Horibata, Shinji; Shinko Hospital Tsuji, Goh; Shinko Hospital Suzuki, Yoko;Draft Kobe Pharmaceutical University, Clinical Pharmaceutical Science Nakayama, Kazuhiko; Shinko Hospital Hatae, Takashi; Kobe Pharmaceutical University Kumagai, Shunichi; Shinko Hospital EMOTO, Noriaki; Kobe Pharmaceutical University, Clinical Pharmaceutical Science; Kobe University Graduate School of Medicine School of Medicine, Division of Cardiovascular Medicine Is the invited manuscript for consideration in a Special ET-16 Kobe 2019 Issue: bosentan, pulmonary arterial hypertension, pharmacogenetics, CHST3, Keyword: CHST13 https://mc06.manuscriptcentral.com/cjpp-pubs Page 1 of 13 Canadian Journal of Physiology and Pharmacology Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension Kennosuke Yorifuji, M.Pharm.1, 2, 3; Yuko Uemura2; Shinji Horibata, M.Pharm.2, 3; Goh Tsuji, M.D., PhD.2, 4; Yoko Suzuki, M.Pharm.1, 5; Kazuhiko Nakayama, M.D., PhD.6; Takashi Hatae, PhD.7; Shunichi Kumagai, M.D., PhD.2, 4; Noriaki Emoto, M.D., PhD.1, 5 1Laboratory of Clinical Pharmaceutical Science, 7 Education and Research Center
    [Show full text]
  • Drugs Affectin the Autonomic Nervous System
    Fundamentals of Medical Pharmacology Paterson Public Schools Written by Néstor Collazo, Ph.D. Jonathan Hodges, M.D. Tatiana Mikhaelovsky, M.D. for Health and Related Professions (H.A.R.P.) Academy March 2007 Course Description This fourth year course is designed to give students in the Health and Related Professions (H.A.R.P.) Academy a general and coherent explanation of the science of pharmacology in terms of its basic concepts and principles. Students will learn the properties and interactions between chemical agents (drugs) and living organisms for the rational and safe use of drugs in the control, prevention, and therapy of human disease. The emphasis will be on the fundamental concepts as they apply to the actions of most prototype drugs. In order to exemplify important underlying principles, many of the agents in current use will be singled out for fuller discussion. The course will include the following topics: ¾ The History of Pharmacology ¾ Terminology Used in Pharmacology ¾ Drug Action on Living Organisms ¾ Principles of Pharmacokinetics ¾ Dose-Response Relationships ¾ Time-Response Relationships ¾ Human Variability: Factors that will modify effects of drugs on individuals ¾ Effects of Drugs Attributable to Varying Modes of Administration ¾ Drug Toxicity ¾ Pharmacologic Aspects of Drug Abuse and Drug Dependence Pre-requisites Students must have completed successfully the following courses: Biology, Chemistry, Anatomy and Physiology, Algebra I and II Credits: 5 credits Basic Principles of Drug Action Introduction to Pharmacology a. Basic Mechanisms of Drug Actions b. Dose-response relationships c. Drug absorption d. Biotransformation of Drugs e. Pharmacokinetics f. Factors Affecting Drug Distribution g. Drug Allergy and Pharmacogenetics h.
    [Show full text]
  • Phosphate Binders As a Cause of Hypothyroidism in Dialysis Patients
    Cataldo et al. BMC Nephrology (2018) 19:155 https://doi.org/10.1186/s12882-018-0947-9 CASE REPORT Open Access Phosphate binders as a cause of hypothyroidism in dialysis patients: practical indications from a review of the literature Emanuela Cataldo1,3, Valeria Columbano1,2, Louise Nielsen1, Lurlynis Gendrot1, Bianca Covella1,3 and Giorgina Barbara Piccoli1,4* Abstract Background: Although fatigue is common in dialysis patients, polypharmacy is seldom listed among its causes. In this report, we describe a dialysis patient who developed severe fatigue due to pharmacological interaction between two commonly prescribed drugs, phosphate binders and levothyroxine. Case Presentation: A 65-year old woman, on dialysis for 17 years, complained of fatigue (weight 54 Kg, height 1.55 m, BMI: 23 Kg/m2; malnutrition inflammation index: 10; Charlson index 9). She had been treated with lithium for about 20 years. A heavy smoker, she was obese and diabetic when young, but stopped treatment after weight loss. She had undergone thyroidectomy for papillary carcinoma, left hemicolectomy for colon adenocarcinoma, left quadrantectomy followed by radiotherapy for ductal mammary adenocarcinoma, subtotal parathyroidectomy for tertiary hyperparathyroidism. At the time of this report, she was on thrice-weekly hemodiafiltration (Daugirdas 2 Kt/V: 1. 6–1.8). Her recent treatment included spironolactone, amlodipine, perindopril, valproate, lamotrigine, levothyroxine, vitamin D, calcium carbonate, sodium polystyrene and sevelamer. After she questioned her doctor about whether her fatigue might be the result of a drug interaction, levothyroxine interference was identified (TSH, previously normal, increased to 13.07 mU/L, after increasing sevelamer dose, and normalized after change of drug schedule).
    [Show full text]
  • Preferred Drug List
    October 2021 Preferred Drug List The Preferred Drug List, administered by CVS Caremark® on behalf of Siemens, is a guide within select therapeutic categories for clients, plan members and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. PLAN MEMBER HEALTH CARE PROVIDER Your benefit plan provides you with a prescription benefit program Your patient is covered under a prescription benefit plan administered administered by CVS Caremark. Ask your doctor to consider by CVS Caremark. As a way to help manage health care costs, prescribing, when medically appropriate, a preferred medicine from authorize generic substitution whenever possible. If you believe a this list. Take this list along when you or a covered family member brand-name product is necessary, consider prescribing a brand name sees a doctor. on this list. Please note: Please note: • Your specific prescription benefit plan design may not cover • Generics should be considered the first line of prescribing. certain products or categories, regardless of their appearance in • This drug list represents a summary of prescription coverage. It is this document. Products recently approved by the U.S. Food and not all-inclusive and does not guarantee coverage.
    [Show full text]
  • Management of Hypopituitarism
    Journal of Clinical Medicine Review Management of Hypopituitarism Krystallenia I. Alexandraki 1 and Ashley B. Grossman 2,3,* 1 Endocrine Unit, 1st Department of Propaedeutic Medicine, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece; [email protected] 2 Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford OX3 7LE, UK 3 Centre for Endocrinology, Barts and the London School of Medicine, London EC1M 6BQ, UK * Correspondence: [email protected] Received: 18 November 2019; Accepted: 2 December 2019; Published: 5 December 2019 Abstract: Hypopituitarism includes all clinical conditions that result in partial or complete failure of the anterior and posterior lobe of the pituitary gland’s ability to secrete hormones. The aim of management is usually to replace the target-hormone of hypothalamo-pituitary-endocrine gland axis with the exceptions of secondary hypogonadism when fertility is required, and growth hormone deficiency (GHD), and to safely minimise both symptoms and clinical signs. Adrenocorticotropic hormone deficiency replacement is best performed with the immediate-release oral glucocorticoid hydrocortisone (HC) in 2–3 divided doses. However, novel once-daily modified-release HC targets a more physiological exposure of glucocorticoids. GHD is treated currently with daily subcutaneous GH, but current research is focusing on the development of once-weekly administration of recombinant GH. Hypogonadism is targeted with testosterone replacement in men and on estrogen replacement therapy in women; when fertility is wanted, replacement targets secondary or tertiary levels of hormonal settings. Thyroid-stimulating hormone replacement therapy follows the rules of primary thyroid gland failure with L-thyroxine replacement.
    [Show full text]
  • Hoosier School Benefit Trust Health and Wellness Center Prescription
    Hoosier School Benefit Trust Health and Wellness Center Prescription Medication Formulary Brand Name Generic Name Strength ZOVIRAX ACYCLOVIR 800MG VENTOLIN HFA ALBUTEROL SULFATE 90 MCG HFA NORVASC AMLODIPINE BESYLATE 5MG AMOXICILLIN AMOXICILLIN 250MG/5ML SUSP ML AMOXICILLIN AMOXICILLIN 250MG AMOXICILLIN AMOXICILLIN 400MG/5ML SUSP ML AMOXICILLIN AMOXICILLIN 500MG CAP AMOXICILLIN AMOXICILLIN 875MG TAB AUGMENTIN AMOXICILLIN/POTASSIUM CLAV 400-57MG/5 SUSP ML AUGMENTIN AMOXICILLIN/POTASSIUM CLAV 500-125MG TAB AUGMENTIN AMOXICILLIN/POTASSIUM CLAV 875-125MG TAB TENORMIN ATENOLOL 50MG TAB LIPITOR ATORVASTATIN CALCIUM 10MG TAB LIPITOR ATORVASTATIN CALCIUM 20MG TAB LIPITOR ATORVASTATIN CALCIUM 40MG TAB ZITHROMAX AZITHROMYCIN 200MG/5ML SUSP ML ZITHROMAX AZITHROMYCIN 250MG TAB TESSALON BENZONATATE 200MG CAP BETAMETHASONE DIPROPIONATE BETAMETHASONE DIPROPIONATE CREAM OMNICEF CEFDINIR 125MG/5ML SUSP ML OMNICEF CEFDINIR 300MG CAP KEFLEX CEPHALEXIN 500MG CAP CIPRO CIPROFLOXACIN HCL 500MG TAB CELEXA CITALOPRAM HYDROBROMIDE 20MG TAB CELEXA CITALOPRAM HYDROBROMIDE 40MG TAB LOTRIMIN CLOTRIMAZOLE 1% CREAM LOTRISONE CLOTRIMAZOLE-BETAMETHASONE CREAM FLEXERIL CYCLOBENZAPRINE HCL 10MG TAB VOLTAREN DICLOFENAC SODIUM 50MG TAB VIBRAMYCIN DOXYCYCLINE HYCLATE 100MG CAP ROMYCIN ERYTHROMYCIN BASE 5MG/G EYE OINT LEXAPRO ESCITALOPRAM OXALATE 20MG TAB TRICOR FENOFIBRATE NANOCRYSTALLIZED 145MG TAB DIFLUCAN FLUCONAZOLE 150MG TAB 1.1.17 Hoosier School Benefit Trust Health and Wellness Center Prescription Medication Formulary Brand Name Generic Name Strength LIDEX FLUOCINONIDE
    [Show full text]
  • Relationships Between Dehydroepiandrosterone Sulfate
    Hormones and Behavior 35, 254–263 (1999) Article ID hbeh.1999.1518, available online at http://www.idealibrary.com on Relationships between Dehydroepiandrosterone Sulfate (DHEAS) and Cortisol (CRT) Plasma Levels and Everyday Memory in Alzheimer’s Disease Patients Compared to Healthy Controls Linda E. Carlson,* Barbara B. Sherwin,*,† and Howard M. Chertkow‡ *Department of Psychology, †Department of Obstetrics and Gynecology, and ‡Department of Clinical Neurosciences, McGill University, Montreal, Canada Received June 25, 1998; revised August 4, 1998; accepted September 23, 1998 Fifty-two age-matched Alzheimer’s disease (AD) pa- and depletion of hippocampal neurons and dendritic tients (26 men, 26 women), mean age 76.2 years, were branching in the CA1 and CA3 layers (Uno, Tarara, assessed with the Rivermead Behavioural Memory Test, Else, Suleman, and Sapolsky, 1989; Sapolsky, Uno, a test of everyday memory, coincident with the measure- Rebert, and Finch, 1990; Uno, Lohmiller, Thieme, ment of plasma cortisol (CRT) and dehydroepiandros- Kemnitz, Engle, Roecker, and Farrel, 1990). In hu- terone sulfate (DHEAS) via radioimmunoassay. The AD patients were compared to a control group of age- and mans, the elevated levels of cortisol (CRT) seen in gender-matched healthy elderly men and women. No individuals with Cushing’s Syndrome were related to differences were found between the AD patients and the a decreased volume of the hippocampus as assessed controls in DHEAS or CRT levels, or in the DHEAS/CRT by MRI (Starkman, Gebarski, Berent, and Shcteingart, ratio. There were no gender differences in DHEAS or 1992). CRT levels, or in the DHEAS/CRT ratio in subjects with Reports of elevated CRT levels in Alzheimer’s dis- AD.
    [Show full text]